University of California, San Diego
(San Diego, CA)
ADRN Clinical Coordinator
858.657.1697
Primary Investigator
Richard L. Gallo, MD, PhD is the founding chairman of the Department of Dermatology at the University of California, San Diego. He is a graduate of the University of Chicago and received his MD & PhD from the University of Rochester. After completion of his dermatology training at Harvard Medical School, Dr. Gallo stayed on and pursued postdoctoral training in Cell and Developmental Biology.
Dr. Gallo’s interest focuses on understanding human immunity through basic and applied research of the innate defense systems of epithelial surfaces. He has contributed to several landmark observations in dermatology including the first description of an antimicrobial peptide in mammalian skin, proof of their essential function in host defense, and the first association defects in antimicrobial peptide production with human diseases such as atopic dermatitis. Dr. Gallo’s work has been supported by numerous grants from the NIH and has authored over 250 publications. In addition to his chairman duties for the UCSD Dermatology Department, Dr. Gallo maintains a busy practice at the VA Medical Center in La Jolla as well as an active translational research laboratory that seeks to improve the knowledge and treatment of skin diseases like atopic dermatitis.
Institution
The UCSD Dermatology Clinical Trials Unit has been dedicated to providing innovative treatments and medications for the treatment of a variety of skin conditions. We aim to advance a deeper understanding of dermatology conditions, and to expand and improve upon the current scope of dermatology treatments. Our team of highly qualified investigators, coordinators and staff are committed to responsible research, with patient safety as the highest priority. The Dermatology Clinical Trials Unit emphasizes interventional research for those suffering from psoriasis, eczema, atopic dermatitis and many other dermatological conditions. In addition to industry sponsored research studies, our department has carried our several investigator initiated trials and are continuing to expand our focus and innovate new treatments. All studies are closely monitored to assess the efficacy and safety of novel and emerging therapies, as well as treatments already FDA-approved and available to patients. Recent studies have investigated a wide variety of treatments including topical creams, biologics and oral medications.